EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial

He Wang iD, Haiwei Dou, Guangying Chen, Yanmin Wei, Hua Li, Shuqiong Xu, Rongzhen Kang, Shanhong Liu, Long Zhang, Nan Li, Hongli Sun, Chi Wang und 8 weitere

The Clinical Respiratory Journal · 2026-07 · 20 (7)

DOI: 10.1111/crj.70204 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 25.06.2026. Verfasst von He Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Pneumonia, Mycoplasma, Mycoplasma pneumoniae, Drugs, Chinese Herbal, Anti-Bacterial Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, Program for Cultivating High-Level Public Health Technical Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma pneumoniae (MP) is a major cause of community‐acquired pneumonia in children, with increasing macrolide resistance complicating treatment. Traditional Chinese Medicine (TCM) provides unique benefits for pediatric respiratory infections.

Purpose

To evaluate the safety and efficacy of Lianhua Qingke (LHQK) tablets as adjunctive therapy in children with M. pneumoniae pneumonia (MPP). Study Design This prospective, multicenter, randomized, double‐blind, placebo‐controlled trial adhered to the Declaration of Helsinki and was registered in the Chinese Clinical Trial Registry (ChiCTR2300078209).

Methods

A total of 160 children aged 4–14 years with mild MPP were randomized 1:1 to receive conventional therapy plus LHQK or conventional therapy plus placebo for 7 days across 13 hospitals over 4 months. Efficacy analysis included 128 participants with centrally confirmed MP infection; safety analysis included all 160. Baseline characteristics were comparable (all p > 0.05), with 98.8% medication compliance in both groups ( p > 0.05). The primary outcome was the major symptom resolution rate by Day 7.

Results

The LHQK group showed a significantly higher major symptom resolution rate (85.9% vs. 65.6%, p < 0.05), with a numerically shorter median time to resolution (4.5 vs. 5.0 days, p = 0.072). LHQK also significantly improved cough and expectoration relief rates (all p < 0.05). No differences were found in laboratory parameters. Adverse event incidence was lower with LHQK (2.5% vs. 8.8%, p > 0.05), with no serious events reported.

Conclusion

LHQK is a safe and effective adjunctive TCM therapy for mild MPP in children, offering significant benefits in respiratory symptom alleviation and a favorable safety profile, with a trend toward shorter recovery time, providing a valuable treatment option amid rising antibiotic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, MycoplasmaMycoplasma pneumoniaeDrugs, Chinese HerbalAnti-Bacterial AgentsHumansChildDouble-Blind MethodFemaleMaleChild, PreschoolAdolescentTreatment OutcomeProspective StudiesTabletsCommunity-Acquired PneumoniaMedicine, Chinese TraditionalCommunity-Acquired Infections

Stichwörter der Autor:innen

Lianhua Qingke tabletsMycoplasma pneumoniae pneumoniachildrenmacrolide resistancerandomized double‐blind controlled trial

Substanzen

Drugs, Chinese HerbalAnti-Bacterial AgentsTablets

Autor:innen und Institutionen

  • Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Beijing Fengtai District Hospital of Traditional Chinese Medicine, Beijing, China.
  • Seventh, Hebei Province People's Hospital, Hebei, China.
  • Hebei Yiling Hospital, Hebei, China.
  • Mianyang Maternal and Child Health Hospital, Sichuan, China.
  • Jintang First People's Hospital, Sichuan, China.

ORCID-Profile: He Wang

Förderung

  • National Key Clinical Specialty Discipline Construction Program of China
  • Program for Cultivating High-Level Public Health Technical Talents

Zitieren

APA

Wang, H., Dou, H., Chen, G., Wei, Y., Li, H., Xu, S., Kang, R., Liu, S., Zhang, L., Li, N., Sun, H., Wang, C., Zhao, J., Yi, J., Song, W., Li, H., Ma, R., Shen, K., Xin, D., & Qi, W. (2026). Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial. The Clinical Respiratory Journal, 20(7). https://doi.org/10.1111/crj.70204

Vancouver

Wang H, Dou H, Chen G, Wei Y, Li H, Xu S, et al. Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial. The Clinical Respiratory Journal. 2026;20(7). doi:10.1111/crj.70204

BibTeX
@article{Wang2026,
  author = {Wang, He and Dou, Haiwei and Chen, Guangying and Wei, Yanmin and Li, Hua and Xu, Shuqiong and Kang, Rongzhen and Liu, Shanhong and Zhang, Long and Li, Nan and Sun, Hongli and Wang, Chi and Zhao, Jie and Yi, Jirong and Song, Wentao and Li, Hongrong and Ma, Rong and Shen, Kunling and Xin, Deli and Qi, Wenjie},
  title = {Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial},
  journal = {The Clinical Respiratory Journal},
  year = {2026},
  volume = {20},
  number = {7},
  doi = {10.1111/crj.70204}
}
Kostenlos starten →